Ftse Mib
34.249,77
0,91%
DAX
18.161,01
1,32%
S&P 500
5.099,96
1,02%
NASDAQ Composite
15.927,90
2,03%
Bitcoin
63.747,44
0,53%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Assistenza
Home Investire Azioni U.S.A. NASDAQ INmune Bio Inc (INMB) INmune Bio Inc (INMB) Notizie

INmune Bio Inc

INMB
11,29
0,45 (4,15%)
27 Apr 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
25/4/202415:00GLOBEINmune Bio Inc. Announces $9.7 Million Registered Direct..
23/4/202414:00GLOBEINmune Bio Inc. Announces 24-Month Stability Validation of..
22/4/202414:00GLOBEINmune Bio Inc. Raises Approximately $4.8 Million in Gross..
08/4/202414:00GLOBEINmune Bio Inc. Presents Data on INB03’s Role as an Immune..
28/3/202421:01GLOBEINmune Bio Inc. Announces Year End 2023 Results and Provides..
26/3/202421:01GLOBEINmune Bio Inc. to Report Fourth Quarter 2023 Financial..
13/3/202413:00GLOBEINmune Bio CSO and Co-Founder Mark Lowdell, Ph.D. Receives..
05/3/202414:00GLOBEINmune Bio Reports Significant EEG Improvement in..
12/2/202415:00GLOBEINmune Bio to Participate in the Oppenheimer 34th Annual..
06/2/202415:00GLOBEINmune Bio to Participate in Baird’s Biotech Discovery..
30/1/202414:02EDGAR2Form 8-K - Current report
30/1/202414:00GLOBEINmune Bio Announces FDA Removal of Clinical Hold for..
16/1/202414:30GLOBEELEVAI Labs, Inc. Acquires Worldwide License Agreement for..
02/1/202422:00EDGAR2Form 8-K - Current report
02/1/202414:00GLOBEINmune Bio Announces First Patient Dosed in a Phase 1/2..
18/12/202322:15EDGAR2Form 8-K - Current report
18/12/202322:05EDGAR2Form 8-A12B/A - Registration of securities [Section 12(b)]:..
18/12/202322:01EDGAR2Form 8-K - Current report
18/12/202322:01GLOBEINmune Bio Provides Update Regarding Global Alzheimer’s..
29/11/202322:00EDGAR2Form 8-K - Current report
29/11/202314:00GLOBEINmune Bio Inc. Demonstrates that INB03 Enhances the Uptake..
27/11/202322:00EDGAR2Form 8-K - Current report
27/11/202314:00GLOBEINmune Bio Receives EMA’s Authorization in France and Spain..
15/11/202322:13EDGAR2Form 8-K - Current report
15/11/202315:00GLOBEINmune Bio Inc. Announces Expansion of Phase II Clinical..
13/11/202317:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/11/202321:13EDGAR2Form 8-K - Current report
01/11/202321:10GLOBEINmune Bio Inc. Announces Third Quarter 2023 Results and..
01/11/202321:05EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
31/10/202321:25EDGAR2Form 8-K - Current report
31/10/202313:00GLOBEINmune Bio Inc. Patent Claims Covering INB16 Cell Line and..
30/10/202314:07GLOBEINmune Bio Inc. Presents Preclinical Data at SITC 2023..
17/10/202314:00GLOBEINmune Bio Inc. Presents New Biomarker and Feasibility Data..
16/10/202315:00GLOBEINmune Bio Inc. to Report Third Quarter 2023 Financial..
07/9/202315:10EDGAR2Form 8-K - Current report
07/9/202315:00GLOBEINmune Bio Inc. to Present at Baird Global Healthcare..
05/9/202322:00EDGAR2Form 8-K - Current report
05/9/202314:00GLOBEINmune Bio Inc. Announces Approval of Clinical Trial..
16/8/202322:41EDGAR2Form 8-K - Current report
16/8/202322:39EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
08/8/202322:01EDGAR2Form 8-K - Current report
07/8/202322:05EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/8/202322:00GLOBEINmune Bio Inc. Announces Second Quarter 2023 Results and..
02/8/202312:02EDGAR2Form 8-K - Current report
01/8/202314:00GLOBEINmune Bio Inc. to Present at the BTIG Virtual ..
31/7/202314:00GLOBEINmune Bio, Inc. to Report Second Quarter 2023 Financial..
27/7/202322:43EDGAR2Form 8-K - Current report
14/7/202322:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/7/202322:00EDGAR2Form 8-K - Current report
12/7/202319:23EDGAR2Form 144 - Report of proposed sale of securities
Apertura: 10,83 Min: 10,83 Max: 11,73
Chiusura: 10,84

La tua Cronologia

NASDAQ
INMB
INmune Bio
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network